After a study revealed higher cancer and other risks with a JAK inhibitor in patients with rheumatoid arthritis, further ...

Celltrion, Inc. today announced that seven abstracts will be presented at the 2026 Digestive Disease Week® (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois. The oral and poster ...

Asahi Kasei initiates phase I trial of AK1940, a novel peptide candidate targeting autoimmune diseases: Tokyo Tuesday, April 21, 2026, 15:00 Hrs [IST] Asahi Kasei, a diversified g ...

HKeybio Tech., a global leader in non-human primate (NHP) experimental animal model research and development, today announced the official launch of the world's first NHP Hidradenitis Suppurativa (HS) ...

A broadcast production company you likely have never heard of is taking the blame for Amazon Prime Video’s mishap during a ...

Comprehensive review led by R3’s Department of Research consolidates emerging evidence on Wharton’s jelly function, ...

Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list. TheFly reported on April 15 that DWTX ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

The effects may also extend to vascular health. Periodontal pathogens have been associated with endothelial dysfunction, an ...

Research links air pollution and heavy metals to accelerated bone loss and higher fracture rates, driven by systemic ...

Malaria remains widespread, with case numbers recently rising again. The Bernhard Nocht Institute for Tropical Medicine (BNITM) has been active in malaria research for decades and collaborates with ...

Researchers conducted an integrated safety analysis using pooled data from phase 2b and 3 clinical trials evaluating bimekizumab in axSpA and PsA.